Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Majid Moshirfar, Joshua S Theis, David S Cha, Kaiden B Porter, Carter J Payne & Phillip C Hoopes. (2023) Influence of Preoperative Parameters on the Ratio of Keratometric Change per Diopter of Attempted Spherical Equivalent (∆K/∆SEQ) for Myopic Correction Within LASIK, PRK, and SMILE. Clinical Ophthalmology 17, pages 2563-2573.
Read now
Read now
Majid Moshirfar, Devon Hori Harvey, Qiancheng Wang, Carter J Payne, David G West & Phillip C Hoopes. (2023) Comparison of Corneal Power Difference Maps with Achieved Myopic Correction Using Scheimpflug Tomography After LASIK, PRK, and SMILE. Clinical Ophthalmology 17, pages 1717-1727.
Read now
Read now
Eileen L. Chang & Lucia Sobrin. (2023) Local versus Systemic Therapy for Noninfectious Uveitis (NIU). Seminars in Ophthalmology 38:1, pages 15-23.
Read now
Read now
JD Sheppard & IP Singh. (2019) Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery. Clinical Ophthalmology 13, pages 1279-1288.
Read now
Read now
Timothy L. Comstock & John D. Sheppard. (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opinion on Pharmacotherapy 19:4, pages 337-353.
Read now
Read now
Articles from other publishers (7)
Xiuwen Zhang, Zhuqing Shen, Hong Sun, Fengjiao Bu & Taomin Huang. (2023) Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis. International Ophthalmology 43:7, pages 2477-2486.
Crossref
Crossref
Zora T. Marlowe, Megan E. Cavet & Martin J. Coffey. (2021) Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%. Ophthalmology and Therapy 11:1, pages 435-441.
Crossref
Crossref
Yingxin Chen, Xifei Wang, Minghong Gao, Ruiyao Gao & Lixin Song. (2021) The effect of loteprednol suspension eye drops after corneal transplantation. BMC Ophthalmology 21:1.
Crossref
Crossref
Mohammud G Musleh, Desta Bokre & Annegret H Dahlmann-Noor. (2019) Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. European Journal of Ophthalmology 30:5, pages 856-866.
Crossref
Crossref
Jason L. Vittitow & Jon I. Williams. (2020) Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children. Journal of Cataract and Refractive Surgery 46:8, pages 1092-1101.
Crossref
Crossref
Sum S. Kwok, Kendrick C. Shih, Yashan Bu, Amy C.-Y. Lo, Tommy C.-Y. Chan, Jimmy S.-M. Lai, Vishal Jhanji & Louis Tong. (2019) Systematic Review on Therapeutic Strategies to Minimize Corneal Stromal Scarring After Injury. Eye & Contact Lens: Science & Clinical Practice 45:6, pages 347-355.
Crossref
Crossref
Megan E. CavetShellise GlogowskiEzra R. LoweEric Phillips. (2019) Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%. Journal of Ocular Pharmacology and Therapeutics 35:5, pages 291-300.
Crossref
Crossref